| abstract |
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions comprising the compound. Methods of using Btk inhibitors, alone or in combination with other therapeutic agents, to treat autoimmune diseases or conditions, heteroimmune diseases or conditions, cancers including lymphomas, and inflammatory diseases or conditions are described. |